CTMX
CytomX Therapeutics Inc
NASDAQ: CTMX · HEALTHCARE · BIOTECHNOLOGY
$4.05
-1.70% today
Updated 2026-04-29
Market cap
$951.18M
P/E ratio
—
P/S ratio
12.48x
EPS (TTM)
$-0.15
Dividend yield
—
52W range
$1 – $8
Volume
7.6M
CytomX Therapeutics Inc (CTMX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
-3.1%
Last 4 quarters
Revenue YoY growth
-98.3%
Most recent quarter
EPS YoY growth
-195.7%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-7.4%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-14.0%
2025-11-06
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-04 | $-0.22 | -134.8% | $4.81 | $4.77 | -0.8% |
| 2025-11-06 | $-0.09 | -80.0% | $4.21 | $3.62 | -14.0% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.09 | $-0.22 | -134.8% | $663000.00 | -98.3% |
| 2025-09-30 | $-0.05 | $-0.09 | -80.0% | $5.96M | -82.2% |
| 2025-06-30 | $-0.06 | $-0.00 | +98.0% | $18.66M | -25.7% |
| 2025-03-31 | $0.13 | $0.27 | +104.2% | $50.92M | +22.8% |
| 2024-12-31 | $-0.11 | $0.23 | +317.2% | $38.09M | +43.2% |
| 2024-09-30 | $-0.17 | $0.07 | +141.2% | $33.43M | +26.7% |
| 2024-06-30 | $-0.14 | $-0.08 | +42.9% | $25.11M | +1.6% |
| 2024-03-31 | $-0.08 | $0.17 | +312.5% | $41.46M | +76.4% |
| 2023-12-31 | $-0.03 | $0.01 | +133.3% | $26.61M | — |
| 2023-09-30 | $-0.19 | $0.04 | +121.1% | $26.38M | — |
| 2023-06-30 | $-0.20 | $-0.02 | +90.0% | $24.72M | — |
| 2023-03-31 | $-0.11 | $-0.05 | +54.5% | $23.50M | — |
Frequently asked questions
Has CytomX Therapeutics Inc beaten earnings estimates?
CytomX Therapeutics Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of -3.1% over the last 4 quarters.
How does CTMX stock react to earnings?
CTMX stock has moved an average of -7.4% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is CytomX Therapeutics Inc's revenue growth rate?
CytomX Therapeutics Inc reported year-over-year revenue growth of -98.3% in its most recent quarter, with EPS growing -195.7% year-over-year.